Senores Pharmaceuticals Ltd
Incorporated in 2015, Senores Pharmaceuticals Ltd manufactures and develops affordable and high-quality complex generics certified by global food and drugs authorities[1]
- Market Cap ₹ 3,178 Cr.
- Current Price ₹ 690
- High / Low ₹ 738 / 435
- Stock P/E 54.3
- Book Value ₹ 171
- Dividend Yield 0.00 %
- ROCE 11.4 %
- ROE 11.8 %
- Face Value ₹ 10.0
Pros
- Debtor days have improved from 177 to 114 days.
Cons
- Stock is trading at 4.04 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company might be capitalizing the interest cost
- Working capital days have increased from 21.7 days to 88.2 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE SmallCap BSE IPO BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|
14 | 35 | 215 | 398 | |
12 | 23 | 173 | 309 | |
Operating Profit | 2 | 13 | 42 | 90 |
OPM % | 14% | 36% | 19% | 23% |
0 | 4 | 3 | 19 | |
Interest | 1 | 2 | 9 | 22 |
Depreciation | 1 | 2 | 10 | 17 |
Profit before tax | 1 | 12 | 25 | 71 |
Tax % | 13% | 32% | -31% | 17% |
1 | 8 | 33 | 58 | |
EPS in Rs | 1.01 | 8.59 | 10.31 | 12.72 |
Dividend Payout % | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 204% |
TTM: | 86% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 290% |
TTM: | 86% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 15% |
Last Year: | 12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|
Equity Capital | 9 | 10 | 31 | 46 |
Reserves | 28 | 36 | 174 | 740 |
15 | 63 | 258 | 315 | |
8 | 23 | 160 | 126 | |
Total Liabilities | 59 | 131 | 622 | 1,227 |
7 | 27 | 235 | 429 | |
CWIP | 8 | 34 | 97 | 44 |
Investments | 15 | 16 | 0 | 0 |
29 | 53 | 289 | 754 | |
Total Assets | 59 | 131 | 622 | 1,227 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|
-10 | -1 | -20 | -46 | |
-24 | -48 | -54 | -429 | |
36 | 46 | 87 | 573 | |
Net Cash Flow | 2 | -3 | 13 | 98 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|
Debtor Days | 506 | 228 | 191 | 114 |
Inventory Days | 135 | 89 | 129 | 114 |
Days Payable | 324 | 388 | 389 | 136 |
Cash Conversion Cycle | 317 | -71 | -70 | 92 |
Working Capital Days | 359 | -7 | -16 | 88 |
ROCE % | 18% | 12% | 11% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
1d - Senores Pharmaceuticals Limited has informed regarding schedule of Analyst / Institutional Investor Meeting on September 02, 2025
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
1d - Senores Pharmaceuticals Limited has informed regarding Newspaper publication of the Notice of the Eighth (8th) Annual General Meeting of the members of the Company
- Notice Of Eighth (8Th) Annual General Meeting To Be Held On September 18, 2025 26 Aug
-
Reg. 34 (1) Annual Report.
26 Aug - AGM on September 18, 2025; Annual Report FY2024-25 filed; e‑voting Sept 15–17, 2025.
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 25 Aug
Concalls
-
Jul 2025Transcript PPT REC
-
May 2025Transcript PPT REC
-
May 2025TranscriptNotesPPT
-
Jan 2025Transcript PPT REC
Business Overview:[1]
SPL is global research driven pharmaceutical company which develops and manufactures
pharmaceutical products for the Regulated Markets of US, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Company develops and manufactures specialty, underpenetrated and complex pharmaceutical products. It also manufactures criticalcare injectables and APIs